News
IBRX
5.12
+6.22%
0.30
ImmunityBio immunotherapy shows positive overall survival in lung cancer trial
ImmunityBio immunotherapy shows positive overall survival in lung cancer trial. Shares of ImmunityBio rose as much as 17% premarket on Thursday. Immunotherapy drug, Anktiva, in non-small cell lung cancer. The first vials of immunotherapy are likely to be available in May 2024.
Seeking Alpha · 9h ago
Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Teradyne, Inc. Shares rose sharply in today's pre-market trading after the company posted upbeat first-quarter results. The company's quarterly sales came in at $599.819 million compared to expectations of $566.310 million. Other stocks moving in pre- market trading include Intelligent Living Application Group and Cidara Therapeutics.
Benzinga · 10h ago
Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA
QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in lung cancer patients. Company says ANKTIVA is an immune cell enhancer that activates NK cells and T cells to rescue checkpoint inhibitors. $100 million in cash-on-hand for launch of AN KTIVA in non-muscle invasive bladder cancer.
Benzinga · 14h ago
IMMUNITYBIO INC - $100 MLN IN NON-DILUTIVE CASH INFUSION WITH ANKTIVA APPROVAL BRINGS CASH-ON-HAND TO APPROXIMATELY $240 MLN FOR LAUNCH OF ANKTIVA
Reuters · 17h ago
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio, Inc. Announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy. The results reinforce ImmunityBio’s belief in the unique mechanism of action of ANKTIVA as a next-generation immunotherapy.
Barchart · 22h ago
ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains
Seeking Alpha · 1d ago
Noteworthy Tuesday Option Activity: IBRX, BKNG, UPST
NASDAQ · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Visa, Tesla, US energy sector
Dow Jones Industrial Average was up 0.77% at 38,535.1. Wall Street's main indexes advanced on Tuesday as growth and chip shares gained. Stocks like General Motors and Spotify rose on upbeat earnings updates ahead of quarterly reports from big technology companies. The top three S&P 500 percentage gainers were Globe Life, Danaher.
Reuters · 2d ago
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
ImmunityBio, Inc. Received FDA approval of its drug ANKTIVA for the treatment of patients with bladder cancer. The global bladder cancer market could reach $11.5 billion by 2032. Company also tends to evaluate the use of AN KTIVA towards other cancer indications.
Seeking Alpha · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Neurocrine, SunPower, NextEra Energy
Dow Jones Industrial Average was up 0.53% at 38,444.3. Stocks like General Motors and Spotify rose on upbeat earnings updates. Growth and chip shares gained as growth and tech shares rose. Neurocrine, SunPower, NextEra Energy among the day's losers.
Reuters · 2d ago
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
ImmunityBio, Inc.'s Anktiva approved by FDA for bladder cancer. The drug faces tough competition from existing treatments and promising therapies in the pipeline. The company's stock jumped nearly 30% on the news of the approval. I believe ImmunityBio's $3 billion enterprise value is already baked in to the company's potential.
Seeking Alpha · 2d ago
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
FDA approves ImmunityBio's Anktiva plus BCG for bladder cancer treatment. The drug is combined with the BCG vaccine for some forms of bladder cancer. The company says the drug is expected to be available in the U.S. By mid-May 2024.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Calix, Fiserv, Quest Diagnostics
U.S. Stocks set to rise at open as some growth and chip stocks gain. Dow e-minis were up 0.28% in early trading. Spotify Technology, Fiserv, Quest Diagnostics among top percentage gainers. Investors digested a raft of quarterly earnings updates.
Reuters · 2d ago
Market-Moving News for April 23rd
Abeona Therapeutics shares are trading lower after the company announced the FDA issued a Complete Response Letter. Cadence Design System shares are also trading lower. The company issued Q2 adjusted EPS and sales guidance below estimates. ImmunityBio has received FDA approval for a cancer drug.
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. Nuwellis shares increased by 24.1% and VolitionRX stock increased by 16.66% during the same time period. Losers Abeona Therapeutics and OncoCyte stock declined by 45.7% and 16.34% respectively.
Benzinga · 2d ago
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Hibbett, Inc. Rose sharply in today's pre-market trading. The company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash. Pineapple Energy Inc. Shares gained 38% to $0.0632 after falling 10% on Monday. ImmunityBio, Inc., AGBA Group Holding Limited and HWH International were among the stocks moving in pre- market trading.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Kimberly-Clark, Spotify, PulteGroup
U.S. Stock index futures advanced on Tuesday. Positive earnings across several sectors got the ball rolling ahead of big tech earning later in the week. Kimberly-Clark, Spotify, PulteGroup were among the top percentage gainers on the NYSE. The Dow e-minis were up 0.16% in premarket trading.
Reuters · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
HWH International (NASDAQ:HWH) stock is rocketing more than 64% alongside heavy pre-market trading. Pineapple Energy shares are soaring close to 40% on plans to regain listing compliance. The biggest pre- market stock movers on Tuesday morning are delisting updates, proposed public offerings, earnings reports and more.
Investorplace · 2d ago
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
ImmunityBio shares of ImmunityBio jumped more than 25% in premarket trading. The immunotherapy company received FDA approval of its treatment for certain patients with bladder cancer. The San Diego company expects Anktiva to be available in the U.S. By mid-May.
Dow Jones · 2d ago
ImmunityBio’s FDA Approval and Planned Equity Expansion
TipRanks · 2d ago
More
Webull provides a variety of real-time IBRX stock news. You can receive the latest news about Immunitybio Inc through multiple platforms. This information may help you make smarter investment decisions.
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.